TY - JOUR
T1 - Association Between Quality of Life and Neurogenic Bowel Symptoms by Bowel Management Program in Spina Bifida
AU - Valeska Halstead, Nadia
AU - Hirsch, Josephine
AU - Rosoklija, Ilina
AU - Rague, James T.
AU - Kim, Soojin
AU - Meyer, Theresa
AU - Larson, Jill E.
AU - Swaroop, Vineeta T.
AU - Bowman, Robin M.
AU - Bowen, Diana K.
AU - Kielb, Stephanie J
AU - Cheng, Earl Y.
AU - Yerkes, Elizabeth B.
AU - Chu, David I.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2024/2
Y1 - 2024/2
N2 - Objective: To compare differences in bowel-specific quality of life (QOL), overall qQOL, and neurogenic bowel dysfunction (NBD) severity by bowel management program in patients with spina bifida (SB). Methods: We performed a retrospective cross-sectional study of patients ≥12 years old at our multidisciplinary SB center who completed both a modified Peristeen NBD questionnaire (assessing bowel symptom severity and bowel-specific QOL) and the Patient-Reported Outcomes Measurement Information System Pediatric Global Health questionnaire (assessing overall QOL). Nested, multivariable models were fit for associations between outcomes and bowel management program (enemas, conservative management, and none). Results: A total of 173 patients, 56.1% female and 64.6% with myelomeningocele, were included in our analysis. Median age was 18.2 years old. Patients reported using enemas (n = 42), conservative management (n = 63), and no bowel program (n = 68). When adjusting for covariates, there was no significant association between bowel-specific QOL nor overall QOL across bowel management programs. However, the use of conservative management compared to enemas was associated with worse bowel symptoms severity (adjusted beta = 2.58, 95%CI = [0.09,5.06]). Additionally, greater bowel symptom severity was significantly associated with lower overall QOL (adjusted beta = − 0.33, 95%CI = [− 0.57,− 0.10]). Conclusion: NBD symptom severity in SB is more strongly associated with QOL than the individual bowel program being utilized. Our findings suggest that different degrees of NBD require different invasiveness of bowel programs, but it is the outcome of the bowel management program and not the specific program itself that is most associated with QOL.
AB - Objective: To compare differences in bowel-specific quality of life (QOL), overall qQOL, and neurogenic bowel dysfunction (NBD) severity by bowel management program in patients with spina bifida (SB). Methods: We performed a retrospective cross-sectional study of patients ≥12 years old at our multidisciplinary SB center who completed both a modified Peristeen NBD questionnaire (assessing bowel symptom severity and bowel-specific QOL) and the Patient-Reported Outcomes Measurement Information System Pediatric Global Health questionnaire (assessing overall QOL). Nested, multivariable models were fit for associations between outcomes and bowel management program (enemas, conservative management, and none). Results: A total of 173 patients, 56.1% female and 64.6% with myelomeningocele, were included in our analysis. Median age was 18.2 years old. Patients reported using enemas (n = 42), conservative management (n = 63), and no bowel program (n = 68). When adjusting for covariates, there was no significant association between bowel-specific QOL nor overall QOL across bowel management programs. However, the use of conservative management compared to enemas was associated with worse bowel symptoms severity (adjusted beta = 2.58, 95%CI = [0.09,5.06]). Additionally, greater bowel symptom severity was significantly associated with lower overall QOL (adjusted beta = − 0.33, 95%CI = [− 0.57,− 0.10]). Conclusion: NBD symptom severity in SB is more strongly associated with QOL than the individual bowel program being utilized. Our findings suggest that different degrees of NBD require different invasiveness of bowel programs, but it is the outcome of the bowel management program and not the specific program itself that is most associated with QOL.
UR - http://www.scopus.com/inward/record.url?scp=85182373974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182373974&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2023.12.012
DO - 10.1016/j.urology.2023.12.012
M3 - Article
C2 - 38159612
AN - SCOPUS:85182373974
SN - 0090-4295
VL - 184
SP - 228
EP - 234
JO - Urology
JF - Urology
ER -